In the light of this data, we further validated the effect of MSCs-breast cancer cells interaction on trastuzumab resistance by determining Ki67, a clinical maker for the rate of proliferation in breast cancer cells and key hallmark of trastuzumab mechanism of action (Fig. 5B and Supplementary Fig. 6). This evidence concerns the gene MKI67 and breast cancer.